Evidence map›Paper›PMID 32283154›Full record

ArticleThe Journal of infection2020

Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19.

Yun Xie, Song Cao, Hui Dong, Qingyun Li, Erzhen Chen, Wenkai Zhang, Luyu Yang, Shouzhi Fu, Ruilan Wang

2 registry-linked trialsAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infection, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 155 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04381858 phase3completednot on this map

Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial

TypeinterventionalSponsorCentenario Hospital Miguel HidalgoRan2020 to 2020Enrolled196ConditionsCOVID-19 PneumoniaArmsPlasma from COVID-19 convalescent patient, Human immunoglobulin
NCT04891172 phase2 / phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Phase II/III Clinical Trial Study to Evaluate Efficacy and Safety of Anti COVID 19 Intravenous Immunoglobulin (C-IVIG) Therapy for Severe COVID-19 Patients

TypeinterventionalSponsorDow University of Health SciencesRan2021 to 2022Enrolled310ConditionsCovid19ArmsAnti COVID 19 Intravenous Immunoglobulin (C-IVIG)
3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Review
  18. Review
  19. Article
  20. Evaluation of the Efficacy and Safety of Intravenous Immunoglobulin (IVIG) in Moderate-to-Severe Hospitalized COVID-19 Patients: A Randomized, Open-Label Parallel-Group Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Yun XieDepartment of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 650 New Songjiang Road, Songjiang, 201600, Shanghai, China.
Song CaoDepartment of Critical Care Medicine, Wuhan Third Hospital,Wuhan University, 216 Guanshan avenue, Hongshan district, Wuhan, 430070, Hubei, China.
Hui DongDepartment of Critical Care Medicine, Wuhan Third Hospital,Wuhan University, 216 Guanshan avenue, Hongshan district, Wuhan, 430070, Hubei, China.
Qingyun LiDepartment of Respiratory, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin two Road, Luwan district, 200020, Shanghai, China.
Erzhen ChenShanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin two Road, Luwan district, 200020, Shanghai, China.
Wenkai ZhangDepartment of Critical Care Medicine, Wuhan Third Hospital,Wuhan University, 216 Guanshan avenue, Hongshan district, Wuhan, 430070, Hubei, China.
Luyu YangDepartment of Critical Care Medicine, Wuhan Third Hospital,Wuhan University, 216 Guanshan avenue, Hongshan district, Wuhan, 430070, Hubei, China.
Shouzhi FuDepartment of Critical Care Medicine, Wuhan Third Hospital,Wuhan University, 216 Guanshan avenue, Hongshan district, Wuhan, 430070, Hubei, China.
Ruilan WangDepartment of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, 650 New Songjiang Road, Songjiang, 201600, Shanghai, China. Electronic address: wangyusun@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CoronavirusCoronavirus InfectionsPandemicsPneumonia, ViralBetacoronavirusCOVID-19HumansImmunoglobulins, IntravenousPrognosisSARS-CoV-2Immunoglobulins, Intravenous

Identifiers

PMID32283154
PMCPMC7151471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.